Results 81 to 90 of about 144,610 (311)

Androgen Receptor: A New Marker to Predict Pathological Complete Response in HER2-Positive Breast Cancer Patients Treated with Trastuzumab Plus Pertuzumab Neoadjuvant Therapy

, 2022
(1) Background: Neoadjuvant therapy is the main therapeutic strategy for human epidermal growth factor receptor 2 (HER2)-positive breast cancer patients, and the combination of trastuzumab and pertuzumab (HP) has become a routine treatment.
Jingming Ye, Ling Xu, Shuang Zhang, Chen Ye, Xuening Duan, Ling Xin, Hong Zhang, Qian Liu, Yuanjia Cheng, Yinhua Liu, Jiayi Li   +10 more
core   +1 more source

“To Anticipate”: Neoadjuvant Therapy in Melanoma with a Focus on Predictive Biomarkers [PDF]

, 2020
Despite surgical resection and adjuvant therapies, stage III melanomas still have a substantial risk of relapse. Neoadjuvant therapy is an emerging strategy that might offer superior efficacy compared to adjuvant therapy.
Ernesto Rossi, Alessandro Marco Minisini, Garutti, M., Garutti M., Minisini A. M., Elisa Bertoli, Buriolla S., Puglisi, F., Giovanni Schinzari, Bertoli, E., Rossi E., Schinzari G., Maria Grazia Vitale, Vitale M. G., Minisini, A. M., Bertoli E., Vitale, M. G., Mattia Garutti, Puglisi F., Schinzari, G., Buriolla, S., Silvia Buriolla, Fabio Puglisi, Rossi, E.   +23 more
core   +1 more source

Inhibition of Focal Adhesion Restricts Chemoresistance in Pancreatic Cancer by Targeting SLC7A11 Mediated Ferroptosis

Advanced Science, EarlyView.
FAK signaling drives chemoresistance and tumor evolution in pancreatic ductal adenocarcinoma. The FAK inhibitor IN10018 restores gemcitabine sensitivity by inducing SLC7A11‐mediated ferroptosis through the PI3K‐Akt pathway and remodeling the tumor microenvironment, reducing mesenchymal components while enhancing CD8+ T‐cell infiltration in preclinical ...
Yingjin Wang, Hui Yang, Baoyuan Zhang, Yongsu Ma, Kuangen Zhang, Peng Wang, Jiapeng Yang, Zaiqi Wang, Rong Liu, Xiaodong Tian, Ning Zhang, Yinmo Yang   +11 more
wiley   +1 more source

Advances for achieving a pathological complete response for rectal cancer after neoadjuvant therapy

Chronic Diseases and Translational Medicine, 2016
Neoadjuvant therapy has become the standard of care for locally advanced mid-low rectal cancer. Pathological complete response (pCR) can be achieved in 12%–38% of patients. Patients with pCR have the most favorable long-term outcomes.
Jian Cui, Hui Fang, Lin Zhang, Yun-Long Wu, Hai-Zeng Zhang   +4 more
doaj   +1 more source

ABHD17C‐Mediated S‐Depalmitoylation of BCL6B Enhances CD24 Transcription to Resist Macrophage Phagocytosis in Pancreatic Cancer

Advanced Science, EarlyView.
ABHD17C‐mediated depalmitoylation of BCL6B at Cys442 blocks its nuclear import and triggers ubiquitin‐dependent degradation, attenuating transcriptional repression of the anti‐phagocytic signal CD24. This mechanism enables pancreatic cancer cells to evade macrophage phagocytosis and fosters an immunosuppressive microenvironment.
Yalu Zhang, Di Cui, Fanzheng Meng, Xu Zhu, Liang Zhu, Liang Wu, Haifeng Hu, Jizhou Wang, Hanhui Yao, Lianxin Liu   +9 more
wiley   +1 more source

Reprogramming the Immune Landscape of Inflammatory Breast Cancer

Advanced Science, EarlyView.
Inflammatory breast cancer is the most lethal subtype of breast cancer and is characterized by an immunosuppressive tumor microenvironment (TME) driven by a complex network of immune cells and inflammatory cytokines, contributing to its aggressiveness and treatment challenges. Immune checkpoint inhibitors, either alone or in combination, show potential
Verena Martinez‐Rodriguez, Suguru Ogata, Xiaoping Wang, Naoto T. Ueno   +3 more
wiley   +1 more source

Neoadjuvant therapy

Journal of the Chinese Medical Association, 2023
Wang, Peng-Hui, Yang, Szu-Ting, Liu, Chia-Hao   +2 more
openaire   +3 more sources

NEOADJUVANT THERAPY FOR PROSTATIC CANCER

The Japanese Journal of Urology, 1993
Neoadjuvant therapy for prostatic cancer might be important to increase cure rates of the disease and preservability of the organs. There were 43 cases in a period of 1975-1990 in which total prostatectomy were performed after neoadjuvant therapy. According to the clinical stage, there were 14 cases in B, 23 in C, 4 in D1 and 2 in D2.
Maeda, Osamu, Saiki, Shigeru, Kinouchi, Toshiaki, Kuroda, Masao, Miki, Tsuneharu, Usami, Michiyuki, Kotake, Toshihiko   +6 more
openaire   +3 more sources

Noninvasive Characterization of Tumor Heterogeneity in HNSCC: From Clinical Utility to Biological Correlates

Advanced Science, EarlyView.
This study establishes a CT‐based radiomics framework to quantify intratumoral heterogeneity (ITH) in HNSCC. Using unsupervised clustering, tumor ROIs and VOIs are analyzed to calculate 2D/3D ITH scores. The score shows strong predictive value for prognosis and immunotherapy response, and is associated with tumor metabolism and immune microenvironment,
Xinwei Chen, Rui Liu, Yuan Zhou, Yin Xiao, Chengmin Feng, Lin Chen, Yanshi Li, Mengna Wang, Zhaobo Cheng, Yuxi Luo, Long Liu, Lijing Niu, Yue Xiang, Juan Peng, Guohua Hu, Min Pan   +15 more
wiley   +1 more source

Neoadjuvant therapy for esophageal cancer

World Journal of Gastrointestinal Oncology, 2014
Esophageal cancer is increasing in incidence more than any other visceral malignancy in North America. Adenocarcinoma has become the most common cell type. Surgery remains the primary treatment modality for locoregional disease. Overall survival with surgery alone has been dismal, with metastatic disease the primary mode of treatment failure after an ...
Rachit D, Shah, Anthony D, Cassano, James P, Neifeld   +2 more
openaire   +2 more sources